Physician profile
Miret Ibrahim
NPI 1467637884
$1,316.64
in general payments reported to CMS, 2019-2025
17 companies · $400 in 2025
The $400 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $34.65 · 2021: $14.67 · 2022: $186 · 2023: $117 · 2024: $430 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $946.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $383.94 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $202.48 | 2022-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $140.58 | 2021-2025 | Wainua, Farxiga |
| Pfizer INC. | $132.58 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $84.03 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $69.90 | 2023-2025 | Verquvo, Bridion |
| Alnylam Pharmaceuticals INC. | $43.36 | 2025 | Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $34.28 | 2023 | Camzyos |
| Amgen INC. | $32.61 | 2024 | Repatha |
| Regeneron Healthcare Solutions, INC. | $29.55 | 2019 | |
| Cardiva Medical, INC. | $28.38 | 2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Chiesi USA, INC. | $27.87 | 2019-2020 | |
| Lantheus Medical Imaging, INC. | $25.67 | 2025 | |
| Bard Peripheral Vascular, INC. | $24.76 | 2025 | Rotarexs 6 F X 135 Cm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.97 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $20.20 | 2022 | |
| Bridgebio Pharma, INC. | $15.48 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miret Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.